Showing results (31-40 of 54) with videos related to
Sort By:
Pageof 6
Reproductive Sciences (Thousand Oaks, Calif.)|November 23, 2012
High frequency of putative ovarian cancer stem cells with CD44/CK19 coexpression is associated with decreased progression-free intervals in patients with recurrent epithelial ovarian cancerMing Liu, Gil Mor, Huan Cheng, et al.American Journal of Obstetrics and Gynecology|July 30, 2013
Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2)Diana P English, Stefania Bellone, Emiliano Cocco, et al.Gynecologic Oncology|August 31, 2014
Taselisib, a selective inhibitor of PIK3CA, is highly effective on PIK3CA-mutated and HER2/neu amplified uterine serous carcinoma in vitro and in vivoSalvatore Lopez, Carlton L Schwab, Emiliano Cocco, et al.Journal of Oncology|September 10, 2011
Prevalence of epithelial ovarian cancer stem cells correlates with recurrence in early-stage ovarian cancerKarina Dahl Steffensen, Ayesha B Alvero, Yang Yang, et al.Gynecologic Oncology|September 10, 2013
HER2/neu gene amplification determines the sensitivity of uterine serous carcinoma cell lines to AZD8055, a novel dual mTORC1/2 inhibitorDiana P English, Dana M Roque, Luisa Carrara, et al.Journal of Contemporary Brachytherapy|April 2, 2015
High-dose-rate vaginal brachytherapy with chemotherapy for surgically staged localized uterine serous carcinomaShari Damast, Susan A Higgins, Elena Ratner, et al.International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 27, 2015
Adjuvant carboplatin, paclitaxel, and vaginal cuff brachytherapy for stage III endometrial cancer: analysis of outcomes and patterns of recurrence based on pathologic characteristicsMelissa Rasar Young, Susan A Higgins, Elena Ratner, et al.Cancer Immunology Research|December 11, 2023
Immune Modulation of Innate and Adaptive Responses Restores Immune Surveillance and Establishes Antitumor Immunologic MemoryAyesha B Alvero, Alexandra Fox, Bhaskara Reddy Madina, et al.International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|February 22, 2014
Phase I clinical trial of the mammalian target of rapamycin inhibitor everolimus in combination with oral topotecan for recurrent and advanced endometrial cancerCarlos Acevedo-Gadea, Alessandro D Santin, Susan A Higgins, et al.Cell Cycle (Georgetown, Tex.)|January 23, 2009
Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistanceAyesha B Alvero, Rui Chen, Han-Hsuan Fu, et al.Pageof 6